Clinigen Group PLC (ISE:CLIN)

Clinigen Group PLC (ISE:CLIN)

Share Price
1,008.00 p
-6 (-0.59 %)
Market Cap
£1,332.74 m
Proactive Investors - Run By Investors For Investors

Clinigen Group PLC

Clinigen (Clinigen Group) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines to improve the quality of people's lives around the world.

We are the global leading experts, trusted by both pharmaceutical and biotech companies and healthcare professionals, in providing access to medicines throughout the lifecycle...

Market: ISE:CLIN
52-week High/Low: 1,069.00p / 716.00p
Sector: Pharma & Biotech
Market Cap: £1,332.74 m
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Clinigen Group PLC

Clinigen Group PLC Snapshot



We believe that doing business responsibly matters, whatever sector you are in. But it is particularly important in the pharmaceutical industry because of the high stakes for the ultimate beneficiaries, the patients, for whom safe access to the right medicine can be the difference between life and death.

What does responsible business mean for Clinigen?

At its heart, responsible business in our industry is about doing our best for the patients. ‘Patient focus’ has become something of a cliché in the pharmaceutical world – but we mean it, as summarised by our mission to deliver ‘the right medicine, to the right patient, at the right time’. Whether a patient needs a marketed, licensed medicine; to receive a medicine by taking part in a clinical trial; or to have specialist access to a medicine that wouldn’t normally be available to them in their country, we look after their needs via their consulting physician. Very few other companies can claim to be as focused on the individual patient as we are – no matter what the circumstances, Clinigen can deliver.


Ensuring the quality of the medicines we deliver is of the utmost importance. The supply of commercial drugs for clinical trials is becoming ever more complex, and, with the significant regulatory changes taking place in this area, the expectations of a specialist service provider in terms of technical and project management capabilities are increasingly demanding.

We use our expertise and resources as a specialty pharmaceutical company (with our own portfolio of medicines) to assure every step in the supply chain for all the vital commercial medicines we handle on behalf of our clients. We ensure that products are properly looked after throughout their life in terms of storage and transportation conditions, but also that we guard against the risk of counterfeit product entering the supply chain. Such systems, processes and checks are the norm for a fully-fledged pharmaceutical company like Clinigen, but are challenging for wholesalers who tend not to have full operational quality management systems.


Our dedicated team of patient access experts enable healthcare professionals all over the world to provide essential medicines to patients with unmet medical needs. Our pharmaceutical and biotech clients often come to us to supply emergency medication, typically with extremely short ‘critical need to medicine dosing’ times. Our 24-hour customer support facilities extend well beyond our direct contact customer services team to a dedicated group of people that support practical, technical and compliance requirements whenever they are needed at a few minutes’ notice, ensuring that a patient in extreme circumstances will get the treatment they need.


A good system of corporate governance is the foundation of all well managed companies, and there are particular requirements for those that are listed. Here you can read our corporate governance statement which demonstrates how we manage our business in accordance with the requirements of being listed on AIM.



Whether it’s a patient, a healthcare professional or a pharmaceutical company, we offer specialist services to provide access to medicines across all three stages of the drug lifecycle.

Using our knowledge, expertise and the dedication of our people, we make extraordinary things happen – making a difference to the lives of patients across the world.


Owning our own products gives us unique insight – we thrive in a complex world!

The phrase ‘customer service’ simply can’t describe what our teams offer. It takes their unique combination of expertise, experience and empathy to deal with the intricacies of achieving right medicine, right patient, right time. It’s about healthcare, logistics, pharmaceuticals, regulatory law, manufacturing, customs law and more, all working in harmony.


There’s a human story behind everything we do. Because of the close relationships we’ve built with healthcare professionals and regulatory bodies, we hear about them first-hand. Difficult and often urgent situations bring out the best in us. We’re proud of the depth of knowledge and the initiative our teams show, 24/7, 365 days a year.


You can find us working across 113 different countries, from 11 geographical locations and in 25 different languages. Our global presence enables us to bring vitally important medicines and expertise nearer to those who need it. Wherever we operate, you’ll find a breadth of experience that reacts and reaches across territories – not only geographically, but in the regulatory and clinical sense too.


We move products globally at every scale imaginable, from bulk shipments to small, temperature-controlled packages. No matter the physical size, you’ll find the same attention to detail. To expedite successfully and efficiently, we follow defined routes, find perfect locations and understand customs agencies inside out. We’ll even select the best courier for a specific product in a particular country.


In a continuously evolving environment, it is vital that we stay at the forefront of our industry.  We add something new to our knowledge every day. It’s precious to us as a business and, above all, vital to the wellbeing of patients. That’s why we encourage joined-up thinking and collaboration across our operations.

Australia & New Zealand



South Africa

United Kingdom

United States

Peter Allen
Indepent Non-Executive

Peter has a wealth of experience and has held key senior positions, including Chairman, CEO and CFO in a number of companies in the healthcare industry, and played a significant role in their growth.

Peter spent 12 years at Celltech Group plc (1992–2004) as CFO and Deputy CEO, six years at ProStaken Group plc as Chairman (2007–2013) and interim CEO (2010–2011) and three years as Chairman of Proximagen plc (2009-2012).


Peter is currently Chairman of Abcam plc, Advanced Medical Solutions Plc and Diurnal Plc and Non-Executive Director of Oxford Nanopore Technologies Ltd and Istesso Ltd.

The Board is satisfied that these external appointments do not impact upon the Chairman's ability to discharge his role at the Company effectively.

Shaun Chilton
Chief Executive Officer

Shaun is the Chief Executive Officer of the Clinigen Group and has the responsibility for the Group achieving its key performance indicators and plays a central role in setting the Group strategy.

Shaun has played a pivotal role in the development of Clinigen, joining the company in January 2012 as Chief Operating Officer, when it was a privately owned company with a turnover of £82m.

He was a key part of the executive team that took Clinigen through IPO in September 2012. Then as deputy CEO in 2015 and CEO from November 2016, has been a fundamental part of the leadership of the impressive strategic growth of the company from £135m market capitalisation in 2012 to its current position as one of the largest companies on AIM on the London Stock Exchange.

In 2017, Shaun oversaw the largest M&A healthcare deal of the year in the UK with the successful acquisition of Quantum, in addition to acquiring the largest supplier of unlicensed medicines in Japan, IMMC.

Shaun was awarded the Entrepreneur of the Year Healthcare (Western Europe) in 2017 and 2018 by the European CEO Awards.

Prior to joining Clinigen, Shaun held senior global strategic, commercial and operational roles at Pfizer, Sanofi, Wolters Kluwer Health and the KnowledgePoint360 Group (now part of UDG Healthcare).


Shaun is currently Chairman of C7 Health ltd, a provider of software and services for the healthcare sector.

The Board is satisfied that this external appointment does not impact upon the CEO's ability to discharge his role at the Company effectively.

Nick Keher
Chief Financial Officer

Nick joined Clinigen in March 2019 from Royal Bank of Canada (RBC) where he was Managing Director and Head of RBC’s European Healthcare equity research team.

At RBC, Nick was consistently ranked as a top five equity analyst in the UK healthcare sector. Prior to joining RBC, Nick was a senior analyst at Investec. Cumulatively, Nick has covered the European healthcare space for over eight years at both RBC and Investec.

Nick began his career at Lloyd’s Pharmacy, registering as a pharmacist before joining GlaxoSmithKline (GSK). At GSK, Nick worked within the Group’s R&D, UK Commercial Operations and Global Manufacturing & Supply Strategy finance teams. Nick is a qualified accountant (ACMA) and a qualified pharmacist (MPharm) having completed his Master’s degree in Pharmacy, Medicinal Chemistry, Pharmaceuticals, Biology and Maths from Aston University.

Nick brings an extensive knowledge of the international pharmaceutical and life sciences industry and will combine this with his financial background to help Clinigen deliver its vision of being the Trusted Global Leader in Access to Medicines.

John Hartup
Senior Independent Non-Executive Director

John has over 30 years’ experience as a corporate lawyer, dealing with corporate finance and commercial contract issues across a number of industries. He was formerly Managing Partner at Ricksons LLP and subsequently became a Partner at DWF LLP.


John is currently the Chairman of the Board of Enigma Group Holdings Ltd.

Ian Nicholson
Independent Non-Executive Director

Ian has considerable experience as both an Executive Director and as a Non-Executive Director. Ian is CEO of F2G Limited.


Ian currently holds positions as Non-Executive Director of Consort Medical plc and Bioventix plc, where he is the Non-Executive Chairman. Ian is also Chairman of the Investment Committee at Cancer Research UK Pioneer Fund, Director of Casewell Consulting Ltd, F2G Ltd, and Wells Stores Ltd, and an Operating Partner at Advent Life Sciences LLP.

Anne Hyland
Independent Non-Executive Director

Anne has a strong track record within the biopharma sector, bringing with her over 25 years of financial experience with both public and private companies.

Anne is a Chartered Accountant (FCA), and Corporate Tax Adviser (CTA – AITI) and holds a degree in Business studies from Trinity College, Dublin. Anne's previous roles include CFO of BBI Diagnostics Group Ltd and FTSE-listed Vectura Group plc. Prior to her role at Vectura, Anne held a number of senior finance positions at Celltech Group plc, Medeva plc and KPMG.


Anne is CFO of Kymab Ltd a private biopharmaceutical company. She is also a Non-Executive Director of Elementis plc, a FTSE-250 global specialty chemicals company.

Alan Boyd
Non-Executive Director

Professor Boyd has accumulated over 30 years extensive medical and policy experience within the pharmaceutical sector, holding senior roles within some of the world’s largest pharmaceutical companies.

He began his pharmaceutical career with Glaxo Group Research Ltd. From 1988, he led ICI’s cardiovascular medical research team, and later assumed the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada.

In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones.

In 2005, Professor Boyd left to set up Boyd Consultants, to focus on aiding and supporting early stage life-science based companies in Europe, North America and Japan.

Professor Boyd is a graduate in Biochemistry and Medicine from the University of Birmingham and is currently a Fellow, and past Chair of the Specialist Advisory Committee in Pharmaceutical Medicine at the Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians, UK.  He was elected President of Faculty in November 2015 to November 2018, following three years as Vice-President. Whilst as President he was also a Council Member of both the Royal College of Physicians, London and the Academy of Medical Royal Colleges, UK.

In November 2009, Professor Boyd was appointed an Honorary Professor in the College of Medical and Dental Sciences at the University of Birmingham Medical School, in recognition of his expertise in medicines development. He was also elected as a Fellow of the Royal College of Physicians, London in April 2018.


Professor Boyd is currently CEO of Boyd Consultants Ltd, a private specialist biopharmaceutical consultancy company. He is also a Director of BaxterBoyd Ltd and Celentyx Ltd.


The following were the significant shareholders as at 28 May 2019.

Number of shares held
% issued share capital
Merian Global Investors  8,634,338 6.52%
Invesco 8,378,760 6.33%
Rathbones 7,871,496
AXA Framlington Investment Managers 6,638,103 5.01%
Octopus Investments  6,284,935 4.75%
Janus Henderson Group 6,064,329 4.58%
Lazard Asset Management 4,807,050 3.63%
Andrew Leaver  4,235,860


General enquiries 

Tel:+44 (0) 1283 495 010

Product enquiries

Tel: +44 (0) 1283 494 340


Clinigen, Pitcairn House, Crown Square, First Avenue, Burton-on-Trent, Staffordshire, DE14 2WW

Tel:+44 (0) 1283 495 010

[email protected]



Clinigen CTS, Pitcairn House, Crown Square, First Avenue, Burton-on-Trent, Staffordshire, DE14 2WW

Tel: +44 (0) 1283 495 010

Fax: +44 (0) 1283 495 011



Clinigen CTS Inc., Three Crescent Drive, Suite 110, Navy Yard Corporate Center, Philadelphia, PA 19112

Tel: +1 (215) 558 7001

Fax: +1 (215) 336 0705

Michael Meade
Numis Securities Limited
The London Stock Exchange Building
10 Paternoster Square
Tel: +44 (0) 20 7260 1000

James Black
Numis Securities Limited
The London Stock Exchange Building
10 Paternoster Square
Tel: +44 (0) 20 7260 1000

Marcus Jackson
RBC Capital Markets
Thames Court
One Queenhithe
Tel: +44 (0) 20 7653 4000

DLA Piper
3 Noble Street

PriceWaterhouseCoopers LLP
Cornwall Court
19 Cornwall Street
B3 2DT

Equiniti Limited
Aspect House
Spencer Road
West Sussex
BN99 6DA

Melanie Toyne-Sewell
Instinctif Partners Limited
65 Gresham Street
Tel: +44 (0) 20 7457 2020
Email: [email protected]

Columns Including CLIN


Market Reports Including CLIN

Video RSS



© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use